Immunotherapy combination sets a new standard of care for extensive-stage small cell lung cancer

The Medical News ·
Health & Medicine United Kingdom

In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase 3 open-label, multicenter,…

Read original article on The Medical News →

Related news